Skip to Content

Andro-Cyp 200 (testosterone) Disease Interactions

There are 11 disease interactions with Andro-Cyp 200 (testosterone):

Major

Androgens (applies to Andro-Cyp 200) carcinoma (male)

Major Potential Hazard, High plausibility. Applicable conditions: Breast Cancer -- Male, Prostate Cancer, Benign Prostatic Hyperplasia

The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate. Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively. Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.

References

  1. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) fluid retention

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Liver Disease, Renal Dysfunction

Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema. The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) hypercalcemia in breast cancer

Major Potential Hazard, Moderate plausibility.

When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis. Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents. If hypercalcemia occurs, therapy should be stopped. The development of hypercalcemia may indicate progression of metastases to the bone.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) hyperlipoproteinemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease, Hyperlipidemia

Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels. These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease. Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen. Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) liver disease

Major Potential Hazard, Low plausibility.

The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice. Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages. These latter toxicities may be fatal and often not recognized until they become life-threatening. Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used. If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) polycythemia

Major Potential Hazard, Moderate plausibility.

Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods. Patients with preexisting polycythemia may experience worsening of their condition. Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Androgens (applies to Andro-Cyp 200) suppression of clotting factors

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding

Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time. Androgen therapy should be administered cautiously in patients with bleeding disorders.

References

  1. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
Major

Testosterone (applies to Andro-Cyp 200) renal/liver disease

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction

The use of testosterone is contraindicated in patients with serious hepatic or renal disease.

Moderate

Androgens (applies to Andro-Cyp 200) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

The metabolic effects of androgenic anabolic steroids may lower blood glucose. Decreased glucose tolerance and increased insulin resistance have also been reported. Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.

References

  1. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
Moderate

Androgens (applies to Andro-Cyp 200) hypercalcemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Hyperparathyroidism

Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia. Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction. Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
Minor

Androgens (applies to Andro-Cyp 200) thyroid function tests

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Hypothyroidism, Hyperthyroidism

When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests. Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however.

References

  1. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn, Kalamazoo, MI.

Andro-Cyp 200 (testosterone) drug interactions

There are 149 drug interactions with Andro-Cyp 200 (testosterone)

Andro-Cyp 200 (testosterone) alcohol/food interactions

There is 1 alcohol/food interaction with Andro-Cyp 200 (testosterone)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.